Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.34 |
| ▸ | CHRNG | P07510 | 1/20 | 0.34 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | CHRND | Q07001 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29640629 | 0.81 | KDM1A (0.36) | TMEM97ADRA2ALMNAMAPTHTT | |
| SCHEMBL23362524 | 0.81 | KDM1A (0.36) | TMEM97ADRA2ALMNAMAPTHTT | |
| SCHEMBL8932584 | 0.76 | MAOA (0.39) | — | |
| SCHEMBL23363148 | 0.76 | KDM4C (0.38) | TMEM97HTR2BSIGMAR1HTTKDM4C | |
| SCHEMBL28768384 | 0.75 | KDM4C (0.33) | KDM4C | |
| SCHEMBL3456675 | 0.72 | ADRA2A (0.35) | ADRA2A | |
| SCHEMBL6484820 | 0.71 | KDM1A (0.37) | HTR2BADRA2ASLC6A2SLC6A4 | |
| SCHEMBL8111497 | 0.71 | HCRTR2 (0.34) | HTR2BSIGMAR1ADRA2ALMNAMAPT | |
| SCHEMBL21178335 | 0.70 | MAP3K14 (0.42) | ADRA2ALMNAMAPTHTTBLM | |
| SCHEMBL12501536 | 0.70 | MAP3K14 (0.42) | ADRA2ALMNAMAPTHTTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263042-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2253333-A2 | Contrast Agents for Myocardial Perfusion Imaging | Lantheus Medical Imaging, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253333-A2 | Contrast Agents for Myocardial Perfusion Imaging | Lantheus Medical Imaging, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1740225-A4 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL MYERS SQUIBB CO (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | CITIZENS BANK, N.A. | 2009-04-23 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485283-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1740225-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105159-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050244332-A1 | Contrast agents for myocardial perfusion imaging | CITIZENS BANK, N.A. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090104118-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | TMEM97 1323/4885HTR2B 1118/4885SIGMAR1 1509/4885 |
| US-20050244332-A1 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | TMEM97 1323/4885HTR2B 1118/4885SIGMAR1 1509/4885 |
| US-20130028837-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | TMEM97 1323/4885HTR2B 1118/4885SIGMAR1 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.